Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

346Citations
Citations of this article
272Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Through exomic sequencing of ten hepatitis C virus (HCV)-associated hepatocellular carcinomas (HCC) and subsequent evaluation of additional affected individuals, we discovered novel inactivating mutations of ARID2 in four major subtypes of HCC (HCV-associated HCC, hepatitis B virus (HBV)-associated HCC, alcohol-associated HCC and HCC with no known etiology). Notably, 18.2% of individuals with HCV-associated HCC in the United States and Europe harbored ARID2 inactivation mutations, suggesting that ARID2 is a tumor suppressor gene that is relatively commonly mutated in this tumor subtype. © 2011 Nature America, Inc. All rights reserved.

Cite

CITATION STYLE

APA

Li, M., Zhao, H., Zhang, X., Wood, L. D., Anders, R. A., Choti, M. A., … Kinzler, K. W. (2011). Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nature Genetics, 43(9), 828–829. https://doi.org/10.1038/ng.903

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free